Evidence map›Paper›PMID 27161628›Full record

ArticleAntimicrobial agents and chemotherapy2016

Antifungal Properties of Cationic Phenylene Ethynylenes and Their Impact on β-Glucan Exposure.

Harry C Pappas, Rina Sylejmani, Matthew S Graus, Patrick L Donabedian, David G Whitten, Aaron K Neumann

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. A Portrait of the OPE as a Biological Agent.Molecules (Basel, Switzerland) · 2021
    Review
  5. Dectin-1-Mediated DC-SIGN Recruitment toLife (Basel, Switzerland) · 2021
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Detergent-induced self-assembly and controllable photosensitizer activity of diester phenylene ethynylenes.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Harry C PappasDepartment of Nanoscience & Microsystems Engineering, University of New Mexico, Albuquerque, New Mexico, USA Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA.
Rina SylejmaniDepartment of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA Department of Chemical & Biological Engineering, University of New Mexico, Albuquerque, New Mexico, USA.
Matthew S GrausDepartment of Nanoscience & Microsystems Engineering, University of New Mexico, Albuquerque, New Mexico, USA Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA.
Patrick L DonabedianDepartment of Nanoscience & Microsystems Engineering, University of New Mexico, Albuquerque, New Mexico, USA Department of Chemical & Biological Engineering, University of New Mexico, Albuquerque, New Mexico, USA.
David G WhittenDepartment of Chemical & Biological Engineering, University of New Mexico, Albuquerque, New Mexico, USA.
Aaron K NeumannDepartment of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA akneumann@salud.unm.edu.
University of New Mexico · US

Funding

Biology of Infectious Diseases &InflammationT32AI007538 · NIAID · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Michelle A Ozbun · 1998 to 2026
$5.2M
NIAID NIH HHS T32 AI007538
6 · The paper itself

Abstract

Candida species are the cause of many bloodstream infections through contamination of indwelling medical devices. These infections account for a 40% mortality rate, posing a significant risk to immunocompromised patients. Traditional treatments against Candida infections include amphotericin B and various azole treatments. Unfortunately, these treatments are associated with high toxicity, and resistant strains have become more prevalent. As a new frontier, light-activated phenylene ethynylenes have shown promising biocidal activity against Gram-positive and -negative bacterial pathogens, as well as the environmental yeast Saccharomyces cerevisiae In this study, we monitored the viability of Candida species after treatment with a cationic conjugated polymer [poly(p-phenylene ethynylene); PPE] or oligomer ["end-only" oligo(p-phenylene ethynylene); EO-OPE] by flow cytometry in order to explore the antifungal properties of these compounds. The oligomer was found to disrupt Candida albicans yeast membrane integrity independent of light activation, while PPE is able to do so only in the presence of light, allowing for some control as to the manner in which cytotoxic effects are induced. The contrast in killing efficacy between the two compounds is likely related to their size difference and their intrinsic abilities to penetrate the fungal cell wall. Unlike EO-OPE-DABCO (where DABCO is quaternized diazabicyclo[2,2,2]octane), PPE-DABCO displayed a strong propensity to associate with soluble β-glucan, which is expected to inhibit its ability to access and perturb the inner cell membrane of Candida yeast. Furthermore, treatment with PPE-DABCO unmasked Candida albicans β-glucan and increased phagocytosis by Dectin-1-expressing HEK-293 cells. In summary, cationic phenylene ethynylenes show promising biocidal activity against pathogenic Candida yeast cells while also exhibiting immunostimulatory effects.

Indexed as

AlkynesAntifungal Agentsbeta-GlucansCandida albicansDectin-1EthersHEK293 CellsHumansLectins, C-TypeAlkynesAntifungal Agentsbeta-GlucansDectin-1EthersLectins, C-Typephenyleneethynylene

Identifiers

PMID27161628
PMCPMC4958233
OpenAlexW2345638691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.